Glaukos (NYSE:GKOS) COO Sells 861 Shares of Stock

Glaukos logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • COO Joseph Gilliam sold 861 Glaukos shares at an average price of $250, totaling $215,250; he retained 71,602 shares after the sale.
  • Glaukos reported quarterly revenue of $211.03 million, up 58% year over year, and EPS of $0.47—$0.57 above the consensus estimate.
  • Shares fell 4.4% to $232.59 in Wednesday trading. Analysts’ consensus rating was “Moderate Buy,” with a $218 price target.
  • MarketBeat previews top five stocks to own in December.

Glaukos Corporation (NYSE:GKOS - Get Free Report) COO Joseph Gilliam sold 861 shares of the company's stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $250.00, for a total transaction of $215,250.00. Following the sale, the chief operating officer owned 71,602 shares of the company's stock, valued at approximately $17,900,500. The trade was a 1.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Glaukos Trading Down 4.4%

Shares of NYSE:GKOS traded down $10.66 on Wednesday, reaching $232.59. 1,132,309 shares of the company traded hands, compared to its average volume of 1,909,791. The business's 50-day simple moving average is $188.17 and its 200 day simple moving average is $148.89. The company has a quick ratio of 4.09, a current ratio of 4.57 and a debt-to-equity ratio of 0.09. Glaukos Corporation has a 52 week low of $91.83 and a 52 week high of $255.18.

Glaukos (NYSE:GKOS - Get Free Report) last issued its earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.57. Glaukos had a negative return on equity of 0.97% and a negative net margin of 24.60%. The company had revenue of $211.03 million during the quarter, compared to analysts' expectations of $168.04 million. During the same period in the prior year, the business posted ($0.16) EPS. Glaukos's quarterly revenue was up 58.0% compared to the same quarter last year. Analysts expect that Glaukos Corporation will post 0.50 earnings per share for the current year.

Hedge Funds Weigh In On Glaukos

A number of hedge funds and other institutional investors have recently made changes to their positions in GKOS. BlackRock Inc. purchased a new position in Glaukos during the second quarter valued at $1,333,318,000. Jupiter Topco LLC purchased a new stake in shares of Glaukos in the second quarter worth $679,614,000. Janus Henderson Group PLC grew its stake in shares of Glaukos by 77.2% in the first quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier's stock worth $575,844,000 after acquiring an additional 2,329,608 shares during the last quarter. Primecap Management Co. CA bought a new position in shares of Glaukos during the second quarter valued at $424,969,000. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Glaukos by 14.4% during the third quarter. Goldman Sachs Group Inc. now owns 1,025,937 shares of the medical instruments supplier's stock valued at $168,449,000 after acquiring an additional 128,916 shares in the last quarter. Institutional investors own 99.04% of the company's stock.

Wall Street Analysts Forecast Growth

GKOS has been the topic of several recent analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Glaukos in a report on Thursday, October 15th. Zacks Research upgraded shares of Glaukos from a "hold" rating to a "strong-buy" rating in a report on Wednesday, October 28th. BTIG Research increased their price target on shares of Glaukos from $234.00 to $252.00 and gave the company a "buy" rating in a research report on Monday. Needham & Company LLC boosted their price objective on shares of Glaukos from $201.00 to $251.00 and gave the company a "buy" rating in a research report on Thursday, October 29th. Finally, Wall Street Zen raised shares of Glaukos from a "buy" rating to a "strong-buy" rating in a research note on Saturday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $218.00.

Check Out Our Latest Research Report on GKOS

Glaukos Company Profile

(Get Free Report)

Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.

Read More

Insider Buying and Selling by Quarter for Glaukos (NYSE:GKOS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Glaukos Right Now?

Before you consider Glaukos, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.

While Glaukos currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines